Masimo Corporation (MASI) 52.97 $MASI Cepheid's (CPHD)

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 4:18 AM

Masimo Corporation (MASI) 52.97 $MASI

Cepheid's (CPHD) Q2 Loss Narrower than Estimate, View Up
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 2:09PM CDT
Cepheid (CPHD) posted second-quarter 2016 adjusted loss per share of 9 cents.
BABY: 39.33 (-0.24), ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), CPHD: 35.33 (+2.63)

GNC Holdings (GNC) Tops Q2 Earnings, Suspends '16 View
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 2:01PM CDT
GNC Holdings (GNC) ended second-quarter 2016 on a disappointing note as its revenue figure failed to meet the Zacks Consensus Estimate.
BABY: 39.33 (-0.24), ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), GNC: 20.41 (+0.13)

ResMed (RMD) Q4 Earnings in Line, Revenues Top Estimates
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:14AM CDT
ResMed ended fiscal 2016 on a modest note, with fourth-quarter revenues beating estimates and earnings meeting the same.
BABY: 39.33 (-0.24), ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), RMD: 68.88 (+3.18)

Thermo Fisher (TMO) Tops Q2 Earnings, Sales; Updates View
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 2:31PM CDT
Thermo Fisher's (TMO) financial numbers squarely beat the Zacks Consensus Estimate in the second quarter
BABY: 39.33 (-0.24), ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), TMO: 158.84 (+0.02)

Mead Johnson (MJN) Tops Q2 Earnings, Sales Down Y/Y (Revised)
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 10:43AM CDT
Mead Johnson's (MJN) second-quarter results were a mixed bag, with the bottom line comfortably beating the Zacks Consensus Estimate and revenues missing the same.
BABY: 39.33 (-0.24), ABMD: 117.97 (+2.94), MJN: 89.20 (-0.69), MASI: 52.97 (+0.39)

Varian Medical (VAR) Beats Q3 Earnings & Sales; View Up
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 10:15AM CDT
Varian Medical Systems Inc. (VAR) reported earnings of $1.22 per share in the third quarter of fiscal 2016, which beat the Zacks Consensus Estimate by a nickel.
BABY: 39.33 (-0.24), ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), VAR: 94.74 (+0.71)

Leading Ohio Critical Access Hospital Adopts Masimo Root(R) with Radius-7(R), Radical-7(R), and Patient SafetyNet(TM) to Create Hospital-Wide Wireless Monitoring and Clinician Notification System
BusinessWire - Thu Jul 28, 7:02AM CDT
Masimo (NASDAQ: MASI) announced today that University Hospitals Geneva Medical Center (UH Geneva), a Critical Access Hospital in Geneva, Ohio, is building a hospital-wide wireless monitoring and clinician notification system using Masimo Patient SafetyNet(TM)* in conjunction with Masimo Root(R) with Radius-7(R) and Masimo Radical-7(R). UH Geneva is part of University Hospitals, based in Cleveland, Ohio.
MASI: 52.97 (+0.39)

Hologic (HOLX) Beats on Q3 Earnings, Sales; '16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 5:29AM CDT
Hologic (HOLX) ended third-quarter fiscal 2016 on a promising note, with both its top and bottom line comfortably exceeding the Zacks Consensus Estimate.
BABY: 39.33 (-0.24), ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), HOLX: 38.49 (+0.22)

Illumina (ILMN) Beats Q2 Earnings, Revenues; EPS View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:12PM CDT
Illumina (ILMN) ended the second quarter on an outstanding note, with both the top and bottom line results comfortably beating the Zacks Consensus Estimate.
ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), CYNO: 54.96 (+1.13), ILMN: 166.35 (-0.07)

Edwards Lifesciences (EW) Tops Q2 Earnings, '16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 11:39AM CDT
Edwards Lifesciences (EW) ended the second quarter on an encouraging note, with its financial numbers squarely beating the Zacks Consensus Estimate.
ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), CYNO: 54.96 (+1.13), EW: 114.52 (+1.53)

Uptrend Call Working As Masimo Stock Rises 31.7% (MASI)
Comtex SmarTrend(R) - Mon Jul 25, 1:14PM CDT
SmarTrend identified an Uptrend for Masimo (NASDAQ:MASI) on February 26th, 2016 at $39.09. In approximately 5 months, Masimo has returned 31.67% as of today's recent price of $51.47.
MASI: 52.97 (+0.39)

Varian Medical: Claymount Collimators Get FDA Registration
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 7:31AM CDT
Varian Medical Systems, Inc. recently received the U.S. Food and Drug Administration (FDA) registration for its Claymount Optica 20 and Optica 40 collimators.
MASI: 52.97 (+0.39), VAR: 94.74 (+0.71), MLAB: 115.63 (-3.92), NVDQ: 10.66 (+0.40)

AngioDynamics (ANGO) Tops Q4 Earnings, '17 View Positive
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 4:14PM CDT
Shares of AngioDynamics Inc. (ANGO) rallied almost 10%, after the company reported impressive fourth quarter fiscal 2016 results.
ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), MLAB: 115.63 (-3.92), ANGO: 16.59 (+0.07)

New Study Assesses Utility of 1st Generation Masimo Pronto(R) Pulse CO-Oximeter(R) with SpHb(R) Spot Check Technology in Evaluating Pediatric Trauma Patients
BusinessWire - Thu Jul 14, 7:03AM CDT
Masimo (NASDAQ: MASI) announced today that in a new study using the 1st Generation Masimo Pronto(R) Pulse CO-Oximeter(R), which noninvasively measures total hemoglobin (SpHb(R)), researchers found that noninvasive and invasive measurements correlated well and that "[g]iven the rapid availability of results and the lack of requirement of venipuncture, noninvasive hemoglobin monitoring may be a valuable adjunct in the initial evaluation and monitoring of pediatric trauma patients."

1)
MASI: 52.97 (+0.39)

MedTech Tailwinds at a Glance: Which Stocks to Buy?
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 5:02PM CDT
MedTech Tailwinds at a Glance: Which Stocks to Buy?
ABMD: 117.97 (+2.94), LDRH: 36.98 (-0.02), MDT: 87.63 (+0.21), PAHC: 20.63 (-0.26), MLAB: 115.63 (-3.92), NUVA: 62.20 (+0.18), BSX: 24.28 (-0.06), BABY: 39.33 (-0.24), SNN: 33.29 (+0.64), JNJ: 125.23 (+0.77), DXCM: 92.23 (+2.67), GWPH: 94.32 (unch), RMD: 68.88 (+3.18), WOOF: 71.34 (+0.25), ABT: 44.75 (+0.30), VIVO: 19.36 (-0.64), MASI: 52.97 (+0.39), TMO: 158.84 (+0.02), CYH: 12.77 (-0.34), HTWR: 57.94 (+0.05), FEIC: 106.42 (+0.12), ISRG: 695.76 (+5.67), CFMS: 6.97 (-0.06), STE: 70.95 (+0.62), STJ: 83.04 (+0.38), XRAY: 64.04 (+0.94), HOLX: 38.49 (+0.22)

Mazor Robotics Introduces Mazor X for Robotic Spine Surgery
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 8:19AM CDT
Mazor Robotics unveils a revolutionary platform for spine surgeries using highly automated robotic technologies.
ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), MDT: 87.63 (+0.21), MZOR: 22.66 (+0.53)

Exactech (EXAC) Scales a 52-Week High on Product Innovation
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 6:56AM CDT
The launch of Acapella One Cervical Spacer System, will boost Exatech's Spine service business to a large extent, fortifying its hold in the space.
ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), EXAC: 27.03 (+0.15), MLAB: 115.63 (-3.92)

Echo Therapeutics Delisted from Nasdaq, Shares Plummet
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 11:35AM CDT
Shares of Echo Therapeutics Inc. (ECTE) plunged 17.3% to close at $1.48 on Jul 11, after the company announced that it has received a delisting notice from the Nasdaq.
ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), MLAB: 115.63 (-3.92)

Masimo Up 33.0% Since SmarTrend Uptrend Call (MASI)
Comtex SmarTrend(R) - Fri Jul 08, 12:46AM CDT
SmarTrend identified an Uptrend for Masimo (NASDAQ:MASI) on February 26th, 2016 at $39.09. In approximately 4 months, Masimo has returned 33.00% as of today's recent price of $51.99.
MASI: 52.97 (+0.39)

TrovaGene Inks Partnership with University of Michigan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:31PM CDT
TrovaGene Inc. (TROV) is collaborating with the University of Michigan to conduct a multi-phased research program using Trovera KRAS ctDNA liquid biopsy test.
ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), TROV: 5.63 (+0.18), MLAB: 115.63 (-3.92)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Home Buying: Unmasking All the Real Budget Costs

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

Paradigm Therapeutics: A Beacon in Rare Diseases

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Dr. Anderson’s Journey: Leadership with Faith and Service

A Life Shaped by Service Dr. Howard Anderson isn't just another name in a glossy award roster—he's a powerhouse of leadership, a chaplain of compassion, and a soldier in spirit. Honored as a Pinnacle Professional Member of The Inner Circle of Excellence, his recognition feels less like an accolade and more like a testament to a life committed to serving others. The...

Special Needs Group Partners with MAST to Enhance Accessibility

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...